Sagimet Biosciences (SGMT) Operating Expenses (2022 - 2026)

Sagimet Biosciences' Operating Expenses history runs 5 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 41.04% year-over-year to $11.7 million in Q1 2026; TTM through Mar 2026 was $48.7 million, a 25.65% decrease from a year earlier, with the FY2025 full-year figure at $56.9 million, up 4.47% from the prior year.
• Operating Expenses advanced to $11.7 million in Q1 2026 per SGMT's latest filing, from $10.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $19.9 million in Q1 2025 and bottomed at $6.8 million in Q1 2023.
• The 5-year median for Operating Expenses is $10.0 million (2023), against an average of $11.1 million.
• Across the five-year window, Operating Expenses soared 126.56% in 2025 and slumped 41.04% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $7.4 million in 2022, then climbed by 28.13% to $9.5 million in 2023, then surged by 92.21% to $18.2 million in 2024, then tumbled by 40.84% to $10.8 million in 2025, then gained by 8.81% to $11.7 million in 2026.
• Per Business Quant, the three latest SGMT Operating Expenses figures stand at $11.7 million (Q1 2026), $10.8 million (Q4 2025), and $14.3 million (Q3 2025).